COLL's 13.5% Drop: ADHD Growth Is Real, but Pain Headwinds Are Still Pressuring Guidance

Why COLL dropped despite a decent profit beat

COLL fell 13.5% in premarket trading to $30.92 after a quarter that was decent on profit but still missed on revenue. The market did not wait for a full debate: it priced the transition as less mature than investors wanted.

Revenue missed, and that mattered

Revenue came in at $199.9 million vs. analyst estimates of $201.2 million, a small miss, while sales still grew only 6.3% year over year. In a company trying to shift from pain to ADHD, even a modest top-line miss can look like evidence that the switch is happening, but not yet fast enough.

Profit did not break. Non-GAAP EPS was $1.92 versus consensus around $1.77, and management also beat adjusted EBITDA expectations. That suggests the income statement was still intact; investors simply wanted stronger proof that the new ADHD engine could offset the legacy pain business more quickly.

The market is judging the speed of the switch

Management set full-year revenue guidance of $840 million at the midpoint, which is above the prior outlook but still below Wall Street expectations. Full-year EBITDA guidance is $457.5 million at the midpoint, also below analyst estimates. Operating margin was 1.9%, down from 18.7% in the same quarter last year, a useful reminder that this transition is still costing the company near-term profitability.

The core debate, then, is not whether ADHD growth is real. It is whether ADHD growth can fill the pain franchise gap quickly enough to restore both revenue size and margins.

Jornay PM and Azstarys are making the ADHD thesis more concrete

The ADHD story is no longer just strategic language. The commercial data are starting to show breadth.

Jornay PM is expanding across prescriptions, revenue, and prescribers

In Q2, Jornay PM prescriptions grew 13.1%, net revenue rose 41% to $46.1 million, and prescribers reached an all-time high of over 30,000. When all three move higher together, it usually means the brand is reaching new offices rather than relying only on existing users to write more.

Management also said awareness, physician favorability, and intent to prescribe have all improved meaningfully. That does not guarantee the next leg of growth, but it does strengthen the case that the commercial funnel is widening.

Azstarys gives Collegium a second ADHD tool

Collegium also reported AZSTARYS Revenue: $12.9 million, reflecting about a month and a half of commercial sales after completing the acquisition in May. Management said integration is now complete, including sales-force training.

This matters because it turns one growing ADHD asset into a two-product franchise. Management said reps are now selling both Jornay PM and Azstarys across the full target base, which gives the company a clearer path to deepening ADHD share with one broader commercial team.

Why the second half matters more

Collegium said it has expanded its ADHD sales force to about 190 reps and expanded its reach to about 27,000 target physician universe. It also said the back-to-school season to support continued momentum for Jornay PM.

That makes the second half more important than the first. If ADHD momentum holds through a high-attention prescribing window, the business can start to look less like a work-in-progress and more like a true second growth engine.

Pain franchise headwinds still drive the guidance debate

The other side of the quarter was older and still more fragile.

Belbuca is holding up, but it is not enough on its own

Belbuca remains the steadier legacy asset, with BELBUCA Net Revenue: $57.7 million, up 10% year-over-year. Management made the same point on the call, saying Belbuca performed well and grew 10% year over year.

Xtampza ER, though, remains a weakness. It generated XTAMPZA ER Net Revenue: $45 million, down 14% year-over-year. That keeps the pain portfolio from looking like a clean cash cow.

NUCYNTA is the real pressure point

The clearest headwind is NUCYNTA. The franchise delivered NUCYNTA Franchise Net Revenue: $35.2 million, down 24% year-over-year, including $5.1 million from profit share on authorized generics. Management also said NUCYNTA was weaker than expected because of pricing pressure in authorized generics, and that this dynamic is now reflected in guidance.

That is why full-year EBITDA matters more than the headline revenue beat in EPS. Management is guiding to $457.5 million of full-year EBITDA at the midpoint, below Wall Street estimates of $482.8 million. If NUCYNTA pricing stabilizes, the gap can narrow. If it does not, ADHD growth has to do more of the heavy lifting.

Financing the transition still looks manageable

For now, financial strain is not the immediate issue. Collegium generated Operating Cash Flow: $71.3 million in Q2 2026 and ended the quarter with Cash and Marketable Securities: $129.5 million. That gives the company some room to fund the ADHD push while the pain mix sorts itself out.

What investors need to see next

The story has not changed. What matters now is execution.

The main positives to track

• ADHD execution stays on track. Investors need proof that integration is now complete and that Azstarys becomes more than an early ramp story.
• Jornay PM momentum holds through the back-to-school season, with awareness, physician favorability, and intent to prescribe have all improved meaningfully translating into sustained growth.
• The pain decline slows. NUCYNTA does not need to bounce back dramatically, but it cannot keep pulling guidance down faster than ADHD can compensate.

What could delay a rerating

If NUCYNTA pricing weakens again, if Azstarys scales much slower than expected, or if the company has to spend more aggressively before ADHD is carrying more weight, the market will likely stay patient.

For now, this looks more like a watchlist setup than a fully confirmed turnaround. The ADHD growth is real, but the stock still needs evidence that it can offset the pain business quickly enough to support guidance.